Physician profile
Debra Rockey
NPI 1477125797
$2,289.88
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $901 · 2023: $998 · 2024: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.89 | 2021-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $298.29 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $272.76 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $237.33 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.27 | 2022-2024 | Jardiance |
| Indivior INC. | $109.55 | 2022-2023 | Sublocade |
| Amgen INC. | $83.47 | 2023-2024 | Otezla, Repatha |
| Myriad Women'S Health, INC. | $78.21 | 2023 | Myrisk |
| Janssen Pharmaceuticals, INC | $78.00 | 2022-2023 | Spravato |
| Novo Nordisk INC | $77.70 | 2021-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $76.48 | 2022-2023 | |
| Exact Sciences Corporation | $60.08 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $50.92 | 2022 | |
| Pfizer INC. | $49.88 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $41.10 | 2023 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.70 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $29.96 | 2021-2022 | |
| Angiodynamics, INC. | $24.53 | 2024 | Auryon Laser System 100-120 Vac |
| Gilead Sciences, INC. | $23.66 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $21.48 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.48 | 2023 | |
| Astellas Pharma US INC | $20.19 | 2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $18.34 | 2022 | |
| Braeburn INC. | $16.01 | 2023 | Brixadi |
| Glaxosmithkline, LLC. | $14.21 | 2023 | Bexsero, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $13.21 | 2023 | |
| Abbott Laboratories | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Rockey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.